Search Medical Condition
Please enter condition
Please choose location from dropdown

Acute Respiratory Distress Syndrome (ARDS) Clinical Trials

A listing of Acute Respiratory Distress Syndrome (ARDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (97) clinical trials

Positive End-expiratory Pressure and Esophageal Catheter Optimal Calibration Volume in ARDS Patients

The use of esophageal balloon catheter to estimate pleural pressure has gained renewed popularity in recent years. Indeed, measurement of transpulmonary pressure may allow a more pathophysiological-based approach to ventilator strategy in acute respiratory distress syndrome (ARDS) patients. Nevertheless, it is well known that esophageal balloon catheter derived parameters can ...

Phase N/A

Screening Expiratory Flow Limitation by Flow-time Curve

Expiratory flow limitation (EFL) is defined as a dynamic condition that expiratory flow cannot be further increased with higher expiratory driving pressure. Under mechanical ventilation, it can cause intrinsic positive end-expiratory pressure (PEEP) and dynamic hyperinflation, and be associated with worse clinical outcome. The detection of EFL however needs special ...

Phase N/A

Acute Respiratory Distress Syndrome(ARDS) in Neonates

Pregnancy risk factors (PRF), such as intrahepatic cholestasis during pregnancy(ICP), hypertensive disorder complicating pregnancy(HDCP) and gestational diabetes mellitus(GDM), are related to NRDS, ARDS and subsequent death. Meantime, it has also been proven that the prevention of PRF reduces the risk of NRDS and ARDS. However, few study reported the relations ...

Phase N/A

Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children

Scientific background. Dysregulated systemic inflammation - characterized by protracted elevation of inflammatory cytokines in the circulation - is a key pathogenetic mechanism for morbidity and mortality in ALI/ARDS, and is associated with tissue insensitivity and/or resistance to inappropriately elevated endogenous glucocorticoids. In one study, prolonged methylprednisolone treatment of ARDS patients ...

Phase

Comparison of Two Methods to Estimate the Lung Recruitment

In this study the investigators aim to compare two common methods to estimate the lung recruitment in ALI/ARDS patients.

Phase N/A

Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

Low volume ventilation may increase number of ventilatory free days and may improve overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, ...

Phase

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study. Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects. The day of infusion will be considered day ...

Phase

Understanding the Role of Genes and Biomarkers in the Blood Clotting Process in Children With Acute Lung Injury

ALI/ARDS is a life-threatening condition that involves inflammation of the lungs and fluid accumulation in the air sacs, which leads to low blood oxygen levels and respiratory failure. Common causes include pneumonia, sepsis, and lung trauma. Symptoms, including breathing difficulty, low blood pressure, and organ failure, usually develop within 24 ...

Phase N/A

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

PROTOCOL OUTLINE: This is a dose escalation study. Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours. Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until the maximum tolerated dose is determined. Patients are followed for 30 days.

Phase

Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)

In previous lab experiments, we observed evidence of pulmonary edema following alveolar epithelial overexpression of VEGF, suggesting a potential role for VEGF in ARDS. In addition, we found that preventing VEGF from reaching its target receptor(s) by overexpressing a soluble form of a VEGF receptor protein prevents edema formation. These ...

Phase N/A